Plain-English translation of NCT07060638 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether treating alcohol use disorder (addiction to alcohol) at the same time as severe alcohol-related liver disease leads to better outcomes than usual care. The study compares two medications — F-652 and — combined with counseling and a medicine called that helps reduce cravings for alcohol, versus standard treatment.
People with severe alcohol-related liver inflammation face high risk of death, and current treatments focus mainly on the liver damage rather than helping patients stop drinking. This trial is designed to find out whether addressing both the liver disease and the alcohol addiction together — rather than separately — can save more lives and prevent serious complications.
You likely qualify if…
You likely don't qualify if…
You will be hospitalized for the first week, during which you'll receive one of two study medications or placebo. On day 7, if you survive the initial phase, you'll be randomly assigned to receive either counseling plus a medication to reduce alcohol cravings, or usual care (brief advice and referral to a support group). If you receive counseling, you'll have sessions during your hospital stay and for the first three months after leaving the hospital. You'll be followed for up to one year, with blood tests and visits to check how you're doing.
AI-generated summary from trial data · Jul 11, 2026 · Not medical advice
United States